NDA 021923 · Bayer Hlthcare
Nexavar
Sorafenib Tosylate · Oral · Kinase Inhibitor
NovelPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Aug 28, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2005
Dec 1, 2005
Approved uses
7
Original approval plus efficacy supplements
Registered trials
760
116 Phase 3, 24 recruiting
FAERS reports
20,631
18,369 serious, 5,085 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Aug 28, 2023.
NEXAVAR is a kinase inhibitor indicated for the treatment of • Unresectable hepatocellular carcinoma ( 1.1 ) • Advanced renal cell carcinoma ( 1.2 ) • Locally recurrent or metastatic, progressive, differentiated thyroid carcinoma (DTC) refractory to radioactive iodine treatment ( 1.3 ) 1.1 Hepatocellular Carcinoma NEXAVAR ® is indicated for the treatment of patients with unresectable hepatocellular carcinoma (HCC). 1.2 Renal Cell Carcinoma NEXAVAR is indicated for the treatment of patients with advanced renal cell carcinoma (RCC). 1.3 Differentiated Thyroid Carcinoma NEXAVAR is indicated for the treatment of patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma (DTC) that is refractory to radioactive iodine treatment.
Mechanism: Sorafenib is a kinase inhibitor that decreases tumor cell proliferation in vitro. Sorafenib was shown to inhibit multiple intracellular (c-CRAF, BRAF and mutant BRAF) and cell surface kinases (KIT, FLT- 3, RET, RET/PTC, VEGFR-1, VEGFR- 2, VEGFR- 3, and PDGFR-ß). Several of these kinases are thought to be involved in tumor cell signaling, angiogenesis and apoptosis. Sorafenib inhibited tumor growth of HCC, RCC, and DTC human tumor xenografts in immunocompromised mice. Reductions in tumor angiogenesis were seen in models of HCC and RCC upon sorafenib treatment, and increases in tumor apoptosis...
Therapeutic areas: Oncology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Dec 22, 2017 Supplement 18 · Efficacy OrphanLetterLabel
- Nov 22, 2013 Supplement 16 · Efficacy · priority review OrphanLabelLetter
- Nov 16, 2007 Supplement 4 · Efficacy · priority review LabelLetter
- Nov 16, 2007 Supplement 7 · Efficacy · priority review LabelLetter
- Nov 16, 2007 Supplement 5 · Efficacy · priority review LabelLetter
- Nov 16, 2007 Supplement 6 · Efficacy · priority review LetterLabel
- Dec 1, 2005 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanLabelReviewLetter
1 products under this application
- NEXAVAR · SORAFENIB TOSYLATE EQ 200MG BASE · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Sorafenib" as an intervention, any sponsor and status, largest first.
- Treatment Protocol for the Use of Sorafenib in Patients With Advanced Renal Cell CarcinomaPivotal-lookingCompleted
BayerBayer (BAYRY)
NCT00111020 · 2,567 participants · Start Jun 2005 · Primary completion Jun 2007
Drug: Sorafenib (Nexavar, BAY43-9006) · For: Carcinoma, Renal Cell
Sites: Bessemer, Alabama; Cullman, Alabama; Mobile, Alabama · 320 sites in all
- Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By SurgeryPivotal-lookingCompleted
National Cancer Institute (NCI)NIH
NCT00326898 · 1,943 participants · Start Apr 24, 2006 · Primary completion Aug 27, 2015
Drug: Sorafenib Tosylate; Sunitinib Malate · For: Clear Cell Renal Cell Carcinoma; Stage I Renal Cell Cancer AJCC v6 and v7; Stage II Renal Cell Cancer AJCC v7 and 1 more
Sites: Birmingham, Alabama; Huntsville, Alabama; Mobile, Alabama · 987 sites in all
- First Line Hepato Cellular Carcinoma (HCC)Pivotal-lookingCompleted
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT00858871 · 1,714 participants · Start May 2009 · Primary completion Jun 2012
Drug: Brivanib; Placebo and 2 more · For: Hepato Cellular Carcinoma (HCC)
Sites: Scottsdale, Arizona; Little Rock, Arkansas; Downey, California · 173 sites in all
- Sorafenib in Treating Patients at Risk of Relapse After Undergoing Surgery to Remove Kidney CancerPivotal-lookingCompleted
Medical Research CouncilGovernment (non-federal)
NCT00492258 · 1,656 participants (planned) · Start Jun 2007 · Primary completion Aug 2012
Drug: sorafenib tosylate · For: Kidney Cancer
Sites: Bournemouth, United Kingdom; Bristol, United Kingdom; Burton-on-Trent, United Kingdom · 39 sites in all
- Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid LeukemiaPivotal-lookingCompleted
National Cancer Institute (NCI)NIH
NCT01371981 · 1,645 participants · Start Jul 6, 2011 · Primary completion Mar 31, 2019
Drug: Asparaginase; Bortezomib and 5 more · For: Acute Myeloid Leukemia; Leukemia Cutis; Myeloid Neoplasm and 1 more
Sites: Birmingham, Alabama; Mobile, Alabama; Mesa, Arizona · 220 sites in all
- Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular CarcinomaPivotal-lookingActive, not recruiting
AstraZenecaAstraZeneca (AZN)
NCT03298451 · 1,324 participants · Start Oct 11, 2017 · Primary completion Aug 27, 2021
Drug: Durvalumab; Tremelimumab (Regimen 1) and 4 more · For: Hepatocellular Carcinoma
Sites: Los Angeles, California; Orange, California; San Francisco, California · 160 sites in all
- An Open-Label, Non-Comparative, Phase III Study of the Raf-Kinase Inhibitor BAY 43-9006 as a Subsequent to First-Line Therapy in Patients With Advanced Renal Cell CarcinomaPivotal-lookingCompleted
BayerBayer (BAYRY)
NCT00492986 · 1,150 participants · Start Oct 2005 · Primary completion Nov 2008
Drug: Nexavar (Sorafenib, BAY43-9006) · For: Carcinoma, Renal Cell
Sites: Bruxelles - Brussel, Belgium; Leuven, Belgium; Århus C, Denmark · 33 sites in all
- Sorafenib as Adjuvant Treatment in the Prevention Of Recurrence of Hepatocellular Carcinoma (STORM)Pivotal-lookingCompleted
BayerBayer (BAYRY)
NCT00692770 · 1,114 participants · Start Aug 15, 2008 · Primary completion Nov 29, 2013
Drug: Nexavar (Sorafenib, BAY43-9006); Placebo · For: Carcinoma, Hepatocellular
Sites: Birmingham, Alabama; Phoenix, Arizona; Los Angeles, California · 199 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- diarrhoea2,963
- palmar-plantar erythrodysaesthesia syndrome2,170
- hepatocellular carcinoma1,899
- fatigue1,800
- off label use1,710
- death1,461
- rash1,461
- decreased appetite1,453
- nausea1,367
- asthenia1,186
- hypertension1,152
- pyrexia1,066
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2005 | 10 |
| 2006 | 1,014 |
| 2007 | 812 |
| 2008 | 848 |
| 2009 | 1,189 |
| 2010 | 1,615 |
| 2011 | 1,476 |
| 2012 | 1,401 |
| 2013 | 912 |
| 2014 | 1,096 |
| 2015 | 1,356 |
| 2016 | 1,100 |
| 2017 | 1,477 |
| 2018 | 1,578 |
| 2019 | 1,030 |
| 2020 | 798 |
| 2021 | 703 |
| 2022 | 562 |
| 2023 | 640 |
| 2024 | 537 |
| 2025 | 291 |
| 2026 | 186 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Nexavar (Sorafenib Tosylate)
2024 spending
$4.3M
Beneficiaries
62
305 claims
Per beneficiary
$70,029
$189.08 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $92,462,007 |
| 2021 | $76,544,741 |
| 2022 | $47,612,504 |
| 2023 | $8,471,542 |
| 2024 | $4,341,768 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.
Finn RS, Qin S, Ikeda M, et al. · N Engl J Med 2020 · Clinical Trial, Phase III, Multicenter Study
- Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma.
Abou-Alfa GK, Lau G, Kudo M, et al. · NEJM Evid 2022 · Randomized Controlled Trial, Clinical Trial, Phase III
- Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Kudo M, Finn RS, Qin S, et al. · Lancet 2018 · Clinical Trial, Phase III, Comparative Study
- Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With FLT3-Internal Tandem Duplication Mutation (SORMAIN).
Burchert A, Bug G, Fritz LV, et al. · J Clin Oncol 2020 · Clinical Trial, Phase II, Multicenter Study
- Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma.
Cheng AL, Qin S, Ikeda M, et al. · J Hepatol 2022 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable HCC.
Rimassa L, Chan SL, Sangro B, et al. · J Hepatol 2025 · Randomized Controlled Trial, Clinical Trial, Phase III
Sponsor: Bayer
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.